

# **Product Sheet**

# H\_ACVR2A HEK-293(ACVR2B KO) Cell Line

Catalog number: GM-C34941

Version 3.3.1.241204

Description	H_ACVR2A HEK-293(ACVR2B KO) Cell Line is a clonal stable HEK-293 cell line that continuously expresses human ACVR2A on the basis of knocking out human ACVR2B.	
Quantity	5E6 Cells per vial,1 mL	
Product Format	1 vial of frozen cells	
Shipping	Shipped on dry ice	
Storage Conditions	Liquid nitrogen immediately upon receipt	
Target	Human_ACVR2A	
Gene ID/Uniprot ID	P27037-1	
Host Cell	HEK-293	
Recovery Medium	DMEM+10% FBS+1% P.S	
Growth medium	DMEM+10% FBS+1% P.S+125 µg/mL Hygromycin	
Note	The cells are very sensitive to antibiotics and should be cultured using the cell growth medium provided by Genomeditech.	
Freezing Medium	90% FBS+10% DMSO	
Growth properties	Adherent	
Growth Conditions	37°C, 5% CO <sub>2</sub>	
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.	
Safety considerations	Biosafety Level 2	
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.	

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507.5th Flore, East District, Building 1.No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!



Genomeditech (Shanghai) Co.,Ltd. Order: +86 021-68455258/50432826/50432825 Toll-free: +86 400 627 9288 Email: service@genomeditech.com

### **Materials**

Reagent	Manufacturer/Catalogue No.
DMEM	Gibco/C11995500BT
Fetal Bovine Serum	Cegrogen biotech/A0500-3010
Pen/Strep	Thermo/15140-122
Hygromycin	Genomeditech/GM-040403
Anti-ACVR2B hIgG1 Antibody(Bimagrumab)	Genomeditech/GM-51148AB
Anti-ACVR2B hIgG1 Antibody(Fab-17G05)	Genomeditech/GM-82350AB

# **Figures**




Figure 1 | H\_ACVR2A HEK-293(ACVR2B KO) Cell Line (Cat. GM-C34941) was determined by flow cytometry using Anti-ACVR2B hIgG1 Antibody(Bimagrumab) (Cat. GM-51148AB).




Figure 2 | H\_ACVR2A HEK-293(ACVR2B KO) Cell Line (Cat. GM-C34941) was determined by flow cytometry using Anti-ACVR2B hIgG1 Antibody(Fab-17G05) (Cat. GM-82350AB).

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507,5th Floor, East District, Building 1, No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!




Figure 3 | The Sanger sequencing of the parental cells of the H\_ACVR2A HEK-293(ACVR2B KO) Cell Line showed successful knockout of ACVR2B.




Figure 4 | The passage stability of the H\_ACVR2A HEK-293(ACVR2B KO) Cell Line (Cat. GM-C34941) was determined by flow cytometry using Anti-ACVR2B hIgG1 Antibody(Bimagrumab) (Cat. GM-51148AB).

# **Cell Recovery**

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at  $-70^{\circ}$ C. Storage at  $-70^{\circ}$ C will result in loss of viability.

- a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 3 minutes).
- b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

吉满生物科技(上海)有限公司 Genomeditech (Shanghai) Co., Ltd

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507,5th Floor, East District, Building 1,No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!



- d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO<sub>2</sub> in air atmosphere is recommended if using the medium described on this product sheet.

# **Cell Freezing**

Freezing Medium: 90% FBS+10% DMSO

- a) Centrifuge at 176 x g for 3 minutes to collect cells.
- b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- c) Aliquot 1 mL into each vial.
- d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

# Cell passage

Growth medium: DMEM+10% FBS+1% P.S+125 µg/mL Hygromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- a) Subculturing is necessary when the cell density reaches 80%. It is recommended to perform subculturing at a ratio of 1:3 to 1:4 every 2-3 days. Ensure that the density does not exceed 80%, as overcrowding can lead to reduced viability due to compression.
- b) Remove and discard culture medium.
- c) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- d) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).
- e) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach.
  Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- f) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- g) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- h) Incubate cultures at 37°C.

#### Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

#### Notes

- a) Upon initial thawing, a higher number of dead cells is observed, which is a normal phenomenon. Significant improvement is seen after adaptation. Once the cells reach a stable state, the number of dead cells decreases after subculturing and the cell growth rate becomes stable.
- b) Ensure that the cell density does not exceed 80%, as overcrowding may lead to reduced viability due to compression.

吉满生物科技(上海)有限公司 Genomeditech (Shanghai) Co., Ltd



## Sequence

#### ACVR2A P27037-1

MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEI VKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLV PLMLIAGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEYVA VKIFPIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVVSWNEL CHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADFGLALKFEAGKSAGDTHGQVG TRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVV VHKKKRPVLRDYWQKHAGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVT NVDFPPKESSL

## **Related Products**

C	GCGR			
H_GCGR Reporter CHO-K1 Cell Line	H_GCGR Reporter HEK-293 Cell Line			
H_GCGR CHO-K1 Cell Line	H_GCGR HEK-293 Cell Line			
Mouse_GCGR HEK-293 Cell Line				
Anti-H_GCGR hIgG2 Antibody(volagidemab)				
GLP1R				
H_GLP1R Reporter CHO-K1 Cell Line	H_GLP1R Reporter HEK-293 Cell Line			
H_GLP1R Reporter HEK-293 DDX35TM Cell Line	Cynomolgus_GLP1R HEK-293 Cell Line			
H_GLP1R CHO-K1 Cell Line	H_GLP1R HEK-293 Cell Line			
Mouse_GLP1R HEK-293 Cell Line				
Anti-GLP1R hIgG1 Antibody(mAb-36986)	Anti-H_GLP1R hIgG1 Antibody(glutazumab)			
FGF21:FGFR				
H_FGF21 Reporter HEK-293 Cell Line				
CALCA(CGRP): CALCRL RAMP				
H_CALCRL RAMP1 Reporter HEK-293 Cell Line	Cynomolgus_CALCRL RAMP1 HEK-293 Cell Line			
H_CALCRL RAMP1 CHO-K1 Cell Line	H_CALCRL RAMP1 HEK-293 Cell Line			
Anti-CALCRL RAMP1 hIgG2 Antibody(Erenumab)				
GIP:GIPR				
H_GIPR Reporter CHO-K1 Cell Line	H_GIPR Reporter HEK-293 Cell Line			
H_GIPR Reporter HEK-293 DDX35TM Cell Line	Cynomolgus_GIPR HEK-293 Cell Line			
H_GIPR CHO-K1 Cell Line	H_GIPR HEK-293 Cell Line			
Mouse_GIPR HEK-293 Cell Line				
Anti-H_GIPR hIgG1 Antibody(AMG-133)				
ACVR2A: ACTRIIB: Active A				
ACVR2A KO HEK-293 Cell Line	Activin A Reporter Cell Line			
H_ACVR2A Reporter Cell Line	H_ACVR2B Reporter Cell Line			
ACVR2B KO HEK-293 Cell Line	H_ACVR2B HEK-293(ACVR2A KO) Cell Line			

吉满生物科技(上海)有限公司 Genomeditech (Shanghai) Co., Ltd

上海市浦东新区康威路 299 号 1 幢东区 505-507 邮编 201315 505-507,5th Floor, East District, Building 1,No.299 Kangwei Road, Pudong New Area, Shanghai 本公司产品仅供科研用途,严禁用于人体治疗! For research use only!



Genomeditech (Shanghai) Co.,Ltd. Order: +86 021-68455258/50432826/50432825 Toll-free: +86 400 627 9288 Email: service@genomeditech.com

Anti-ACVR2B hIgG1 Antibody(Bimagrumab)	Anti-ACVR2B hIgG1 Antibody(Fab-17G05)		
Anti-ACVR2B mIgG2a Antibody(Bimagrumab)	Anti-H_ACVR2B hIgG1 Reference Antibody(Bimbio)		
Biotinylated Human ACVR2A Protein; His-Avi Tag	Biotinylated Human ACVR2B Protein; His-Avi Tag		
Biotinylated Mouse ACVR2A Protein; His-Avi Tag	Biotinylated Mouse ACVR2B Protein; His-Avi Tag		
Human Activin A Protein; His Tag	Human Activin B Protein; His Tag		
Human ACVR2A Protein; hFc Tag	Human ACVR2A Protein; His Tag		
Human ACVR2B Protein; hFc Tag	Human ACVR2B Protein; His Tag		
Mouse ACVR2B Protein; His Tag			
AMY: CALCR RAMP			
H_CALCR RAMP3(AMY3) Reporter CHO-K1 Cell Line	H_CALCR Reporter CHO-K1 Cell Line		

# **Limited Use License Agreement**

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.